neurofilament light chain in serum/plasma
Jump to navigation
Jump to search
Pathology
Indications
- identification of clinical relapse in multiple sclerosis
- prognosis after cardiac arrest[2]
- prognosis in patients with Guillain-Barre syndrome[6]
- may be elevated in the early chronic phase of traumatic brain injury[10]
- evaluation of dementia
Clinical significance
- serum levels significantly higher in patients with MRI- confirmed subclinical multiple sclerosis disease activity
- serum neurofilament light chain at 24 hours after cardiac arrest predicts long-term poor neurologic outcome[2]
- serum levels higher in multiple system atrophy or progressive supranuclear palsy than in Parkinson's disease & healthy controls
- levels in plasma correspond with hallmarks of Alzheimer's disease progression[4]
- levels in plasma predict onset of MCI in familial Alzheimer's disease type 3 3 years prior[5]
- plasma levels are elevated in frontotemporal dementia & in Alzheimer's disease[7]
- plasma levels cannot distinguish frontotemporal dementia from Alzheimer's disease[7]
- predicts future dementia risk in cerebral small vessel disease[8]
- strongly associated with brain atrophy in multiple areas, white matter alterations, & changes in global cognition[9]
- higher plasma NfL is associated with higher risk of cardiovascular disease, mortality from heart failure, & kidney disease[11]
- 5x higher concentrations of serum NfL associated with increased risk of overall mortality (RR=2.13)[12]
More general terms
Additional terms
References
- ↑ Jenkins K Serum Biomarker May Predict Relapse in MS High NF-L levels could identify subclinical disease activity. MedPage Today. Nov 30, 2017
Varhaug KN, Barro C, Bjornevik K et al Neurofilament light chain predicts disease activity in relapsing-remitting MS Neurol. Published Online Nov 29, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29209636 <Internet> http://nn.neurology.org/content/5/1/e422 - ↑ 2.0 2.1 2.2 Moseby-Knappe M, Mattsson N, Nielsen N et al Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurol. Published online October 29, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30383090 https://jamanetwork.com/journals/jamaneurology/fullarticle/2709115
- ↑ Marques TM, van Rumund A, Oeckl P et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 2019 Mar 26;92(13):e1479-e1486 ePub: Feb 27 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30814322 https://n.neurology.org/content/92/13/e1479
- ↑ 4.0 4.1 George J Blood Test Tracks Alzheimer's Progression. https://www.medpagetoday.com/neurology/alzheimersdisease/79366
Mattsson N, Cullen NC, Andreasson U et al Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. Published online April 22, 2019. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31009028 https://jamanetwork.com/journals/jamaneurology/article-abstract/2731440 - ↑ 5.0 5.1 Quiroz YT et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neurol 2020 Jun; 19:513. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32470423 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30137-X/fulltext
- ↑ 6.0 6.1 George J Blood Biomarker Predicts Guillain-Barre Outcomes - Neurofilament light may help monitor disease severity, help improve prognosis. MedPage Today November 13, 2020 httpi://www.medpagetoday.com/neurology/generalneurology/89669
Martin-Aguilar L, et al Serum neurofilament light chain predicts long-term prognosis in Guillain-Barre syndrome patients. J Neurol Neurosurg Psychiatry 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33154183 https://jnnp.bmj.com/content/early/2020/11/05/jnnp-2020-323899
Jacobs BC Neurofilament light chain as biomarker for axonal damage in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33154185 https://jnnp.bmj.com/content/early/2020/11/05/jnnp-2020-324308 - ↑ 7.0 7.1 7.2 Illan-Gala I, Lleo A, Karydas A et al Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease. Neurology 2020 Nov 16; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33199433 https://n.neurology.org/content/96/5/e671
- ↑ 8.0 8.1 8.2 Egle M, Loubiere L, Maceski A et al Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. J Neurol Neurosurg Psychiatry. Feb 8, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33558370 https://jnnp.bmj.com/content/early/2021/02/08/jnnp-2020-325681.info
- ↑ 9.0 9.1 George J Blood-Based Markers Tied to Brain Cell and Memory Loss. Another step closer to clinical utility for tracking neurodegeneration. MedPage Today April 16, 2021 https://www.medpagetoday.com/meetingcoverage/aan/92140
Marks J, et al Comparison of neurofilament light and total tau as blood-based biomarkers of neurodegeneration: associations with cognition and neuroimaging outcomes. American Academy of Neurology (AAN) 2021. - ↑ 10.0 10.1 Newcombe VFJ et al. Post-acute blood biomarkers and disease progression in traumatic brain injury. Brain 2022 Apr 4; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35377407 https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awac126/6563212
- ↑ 11.0 11.1 Dark HE, Paterson C, Daya GN et al Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk. Ann Neurol. 2023. Oct 6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37801487 https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26817
- ↑ 12.0 12.1 Halloway S et al Serum total tau, neurofilament light, and glial fibrillary acidic protein are associated with mortality in a population study. J Am Geriatr Soc. 2024 Jan;72(1):149-159 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37818793 https://agsjournals.onlinelibrary.wiley.com/doi/full/10.1111/jgs.18632